You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 8,287,905

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,287,905

Title:	Pharmaceutical composition of nanoparticles
Abstract:	The invention discloses a composition of chitosan-shelled nanoparticles and methods of manufacturing. The chitosan-shelled nanoparticles are characterized with a positive surface charge and enhanced epithelial permeability for oral drug delivery.
Inventor(s):	Sung; Hsing-Wen (Hsinchu, TW), Chuang; Er-Yuan (Hsinchu, TW), Nguyen; Ha Giang Thi (Hsinchu, TW), Su; Fang Yi (Hsinchu, TW), Sonaje; Kiran (Hsinchu, TW), Tu; Hosheng (Newport Beach, CA)
Assignee:	GP Medical, Inc. (Newport Beach, CA) National Tsing Hua Univresity (Hsinchu, TW)
Application Number:	13/438,764
Patent Claims:	1. A composition of nanoparticles comprising at least one bioactive agent and a compound having enhanced gastrointestinal enzymatic inhibition property for oral delivery, wherein said compound the has a high binding affinity for calcium, thus enhancing said gastrointestinal enzymatic inhibition, and wherein said nanoparticles consist of positively charged chitosan, optionally a zero-charge substance and a negatively charge substrate, wherein said negatively charged substrate is neutralized with a portion of said positively charged chitosan in a core portion of said nanoparticles. 2. The composition of claim 1, wherein said composition is loaded in an enteric-coated capsule. 3. The composition of claim 2, wherein said capsule further comprises a pharmaceutically acceptable carrier, diluent, excipient, solubilizer, bubbling agent, or emulsifier. 4. The composition of claim 1, wherein said chitosan is selected from the group consisting of N-trimethyl chitosan (TMC), low MW-chitosan, EDTA-chitosan, pegylated chitosan (PEG-chitosan), mono-N-carboxymethyl chitosan (MCC), N-palmitoyl chitosan (NPCS), chitosan derivatives, and combinations thereof. 5. The composition of claim 1, wherein said negatively charged substrate is selected from the group consisting of .gamma.-PGA, .alpha.-PGA, PGA derivatives, PGA-complexone, salts of PGA, and combinations thereof. 6. The composition of claim 1, wherein said compound is a polyaminocarboxylate or a non-polyaminocarboxylate. 7. The composition of claim 6, wherein said polyaminocarboxylate is selected from the group consisting of ethylene diamine tetraacetic acid (EDTA), nitrilotriacetate (NTA), ethylenediaminediacetate (EDDA), ethylene glycol tetraacetic acid (EGTA), diethylene triamine pentaacetic acid (DTPA), iminodiacetic acid (IDA), 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), 1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid (DOTA), and 2,2',2''-(1,4,7-triazonane-1,4,7-triyl)triacetic acid (NOTA). 8. The composition of claim 6, wherein said non-polyaminocarboxylate is dipicolinic acid or deferoxamine. 9. The composition of claim 1, wherein said bioactive agent is a pegylated bioactive agent. 10. The composition of claim 1, wherein said bioactive agent is an anti-diabetic drug. 11. The composition of claim 10, wherein said anti-diabetic drug is selected from the group consisting of insulin, an insulin analog, GLP-1, a GLP-1 analog, an insulin sensitizer, an insulin secretagogue, an inhibitor of dipeptidyl peptidase 4, metformin, alpha-glucosidase inhibitors, amylin analog, sodium-glucose co-transporter type 2 (SGLT2) inhibitors, benfluorex, tolrestat, and combinations thereof. 12. The composition of claim 1, wherein said bioactive agent is exenatide, liraglutide, albiglutide, lixisenatide, or taspoglutide. 13. The composition of claim 1, wherein said bioactive agent is selected from the group consisting of alpha-glucosidase inhibitors, amylin analog, osteocalcin, benfluorex, GLP-2, and tolrestat. 14. The composition of claim 1, wherein said bioactive agent is a monoclonal antibody. 15. The composition of claim 1, wherein said bioactive agent is a hormone, protein, or a peptide. 16. The composition of claim 1, wherein said bioactive agent is a growth hormone. 17. The composition of claim 1, wherein said bioactive agent is an interferon, interleukin, or erythropoietin, colony stimulating factor, tumor necrosis factor, tumor necrosis factor inhibitor, and melanocyte-stimulating hormone. 18. The composition of claim 1, wherein said bioactive agent is an anti-inflammatory drug, an anti-epileptic drug, an antibiotic, or an Alzheimer's antagonist.

Details for Patent 8,287,905

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	04/15/2014	⤷ Try a Trial	2025-01-04
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471	07/27/2016	⤷ Try a Trial	2025-01-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.